Search Within

Sergio Andres Giralt

Formats
  1. Meeting Abstract (642)
  2. Journal Article (374)
  3. Research Letter (19)
  4. Review (15)
  5. Guidelines (5)
  6. Editorial (4)
  7. Book Section (3)
  8. Correspondence (3)
Groups
  1. Bone Marrow Transplant (1065)
  2. Center for Hematologic Malignancies (1065)
  3. Department of Medicine (1065)
  4. Hematologic Malignancies, Division of (1065)
  5. Survivorship Research (699)
  6. CTCR Scholars (553)

More Groups

People
  1. Miguel-Angel Perales (428)
  2. Sean Devlin (379)
  3. Gunjan Shah (308)
  4. Michael Scordo (276)
  5. Heather Landau (260)
  6. Ann Jakubowski (241)

More People

Years
  1. 2025 (14)
  2. 2024 (65)
  3. 2023 (104)
  4. 2022 (77)
  5. 2021 (66)
  6. 2020 (91)

More Years

Publications
  1. Blood (314)
  2. Biology of Blood and Marrow Transplantation (275)
  3. Bone Marrow Transplantation (80)
  4. Clinical Lymphoma, Myeloma and Leukemia (60)
  5. Journal of Clinical Oncology (40)
  6. Transplantation and Cellular Therapy (36)

More Publications

Publishers
  1. Elsevier Inc. (384)
  2. American Society of Hematology (348)
  3. Nature Publishing Group (109)
  4. American Society of Clinical Oncology (42)
  5. Taylor & Francis Group (35)
  6. Ferrata Storti Foundation (13)

More Publishers

Results (1065)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results of a phase 1 open label dose escalation trial of AB-205 (allogeneic engineered endothelial cell therapy) in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT)
    Meeting Abstract

    Scordo, M.; Budde, L. E.; Abedi, M.; Mulroney, C.; Fakhri, B.; Pawarode, A.; Dholaria, B.; Kavalerchik, E.; Aggarwal, S. K.; Qazilbash, M. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Secondary graft-versus-host disease (GVHD) prophylaxis with oral proteasome inhibitor ixazomib is associated with low incidence of recurrent, late acute and chronic GVHD and facilitated calcineurin inhibitor taper within the first year post allogeneic stem cell transplantation
    Meeting Abstract

    Rodriguez, N.; Lee, J.; Flynn, L.; Murray, F.; Devlin, S.; Izquierdo, C. S.; Cho, C.; Dahi, P. B.; Giralt, S. A.; Sauter, C. S.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Rabbit anti-thymocyte globulin exposure (rATG) in CD34+ selected hematopoietic cell transplantation and its impact on immune reconstitution and outcomes in children and adults
    Meeting Abstract

    Lakkaraja, M.; Scordo, M.; Mauguen, A.; Cho, C.; Devlin, S.; Avecilla, S. T.; Boulad, F.; Cancio, M. I.; Curran, K. J.; Jakubowski, A. A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas
    Meeting Abstract

    Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • High doses of targeted radiation with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] do not correlate with incidence of mucositis, febrile neutropenia or sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Gyurkocza, B.; Nath, R.; Choe, H.; Seropian, S.; Stiff, P. J.; Abhyankar, S.; Agura, E.; Litzow, M.; Tomlinson, B. K.; Chen, G. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Personalized targeted radioimmunotherapy with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] in patients with active relapsed or refractory acute myeloid leukemia results in successful donor hematopoietic cells engraftment with the timing of engraftment not related to the radiation dose delivered
    Meeting Abstract

    Gyurkocza, B.; Nath, R.; Choe, H.; Seropian, S.; Stiff, P. J.; Abhyankar, S.; Agura, E.; Litzow, M.; Tomlinson, B. K.; Chen, G. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save